25 completed, 2 terminated, 2 unknown, 1 active not recruiting. 32 Phase 3, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 32 | Completed 25, Terminated 2, Unknown 2, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 10 | Completed 8, Terminated 1, Unknown 1 |
Follow Impulsive Behavior: new trials by email Literature Review of Impulsive Behavior trials Research Report on Impulsive Behavior
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PeRiopEratiVE SmokiNg CessaTion Trial Cytisine, Video Messaging - Smoking (Tobacco) Addiction, Smoking Cessation | Phase 3 | Active not recruiting | Population Health Research Institute | 1720 | 2024-01-15 | 2024-10-03 |
| NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions Nalmefene, Placebo - Behavioural Addiction | Phase 3 | Recruiting | Nantes University Hospital | 266 | 2023-03-31 | 2025-02-12 |
| Oral Naltrexone In Pediatric Eating Disorders Naltrexone Hydrochloride, Control - Anorexia Nervosa/Bulimia, Anorexia in Adolescence | Phase 2 / Phase 3 | Terminated | Rosemary Claire Roden | 9 | 2022-04-22 | 2025-08-19 |
| Perioperative Pregabalin in Ureteroscopy Pregabalin 300mg, Placebo oral tablet - Kidney Stone, Pain, Postoperative | Phase 2 / Phase 3 | Completed | University of Missouri-Columbia | 118 | 2020-06-01 | 2025-11-12 |
| Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12 Mexidol, Placebo, Mexidol + Placebo - Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms | Phase 3 | Completed | Pharmasoft | 333 | 2019-07-13 | 2025-08-17 |
| Functional Magnetic Resonance Imaging (fMRI) Exploration of Neurocognitive Processes Involved in Food Addiction (FA) in Obese Patients: Towards New Phenotypic Markers for an Optimized Care Pathway fMRI, Indirect calorimetry, Bioimpedance - Obesity | Phase 2 / Phase 3 | Completed | Rennes University Hospital | 47 | 2018-04-26 | 2023-08-01 |
| Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL Naltrexone, Placebo, Buprenorphine - Opioid Use Disorder | Phase 3 | Completed | Alkermes, Inc. | 101 | 2016-04-01 | 2019-02-12 |
| Lamotrigine for Ketamine Dependence Trial Lamotrigine, Placebo - Addiction | Phase 2 / Phase 3 | Completed | Taipei City Hospital | 30 | 2015-09-01 | 2018-02-01 |
| Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity Brexpiprazole - Schizophrenia With Impulsivity | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 38 | 2015-02-01 | 2018-11-08 |
| The Safety and Efficacy of a Compound Natural Health Product in Children With Attention Deficit Hyperactivity Disorder (ADHD) Compound Natural Health Product, Placebo - Attention Deficit Hyperactivity Disorder | Phase 3 | Completed | The Canadian College of Naturopathic Medicine | 16 | 2013-11-01 | 2016-01-28 |
| Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks Topiramate, Placebo Comparator - Prader-Willi Syndrome | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 69 | 2012-12-01 | 2018-04-11 |
| Cocaine Use Reduction With Buprenorphine Buprenorphine + Naltrexone, Placebo + Naltrexone - Cocaine Dependence | Phase 2 / Phase 3 | Completed | University of California, Los Angeles | 302 | 2011-09-01 | 2021-10-29 |
| Tobacco Intervention in Buprenorphine Treatment Innovative System, Standard Treatment Control (STC) - Tobacco Dependence | Phase 3 | Completed | University of California, San Francisco | 175 | 2011-04-01 | 2018-11-13 |
| Aripiprazole Effects on Alcohol Drinking and Craving Aripiprazole, Placebo - Alcohol Dependence | Phase 3 | Completed | Medical University of South Carolina | 99 | 2011-02-01 | 2017-08-08 |
| Integrated Cognitive Behavioral Therapy (ICBT) for Posttraumatic Stress Disorder (PTSD) and Substance Use Disorders Integrated Cognitive Behavioral Therapy, Treatment-as-usual - Stress Disorder, Post-Traumatic, Substance-Related Disorders | Phase 3 | Completed | Dartmouth-Hitchcock Medical Center | 56 | 2011-02-01 | 2015-10-26 |
| Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting Methylphenidate Hydrochloride Extended Release Capsule, Placebo - Attention Deficit Hyperactivity Disorder, ADHD | Phase 3 | Completed | Rhodes Pharmaceuticals, L.P. | 26 | 2011-01-19 | 2022-12-13 |
| Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment Cognitive Behavioral Therapy, Individual Addiction Counseling, Treatment-as-usual - Stress Disorders, Post-Traumatic, Substance-Related Disorders | Phase 3 | Completed | Dartmouth-Hitchcock Medical Center | 443 | 2010-12-01 | 2015-02-16 |
| Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD Methylphenidate Hydrochloride Extended Release Capsules, Placebo - Attention Deficit Hyperactivity Disorder, ADHD | Phase 3 | Completed | Rhodes Pharmaceuticals, L.P. | 230 | 2010-11-01 | 2023-02-22 |
| Study on the Possible Effects of Diet Supplementation With Essential Fatty Acids in Chocolate Craving Volunteers Flaxseed oil, Paraffin + # 2 dye - Addictive Behavior, Abstinence Syndrome | Phase 2 / Phase 3 | Completed | Federal University of São Paulo | 30 | 2010-08-01 | 2011-07-12 |
| Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction Modafinil and PET (brain imaging), placebo - Cocaine Addiction, Cocaine Dependence | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 29 | 2009-04-01 | 2013-04-11 |
Showing 20 of 32. Sign in to see all of them.
Behavior, Addictive (18) · Substance-Related Disorders (8) · Attention Deficit Disorder with Hyperactivity (5) · Opioid-Related Disorders (5) · Alcoholism (3) · Cocaine-Related Disorders (3) · Compulsive Behavior (3) · Spasm (3) · Anxiety Disorders (2) · Feeding and Eating Disorders (2) · Food Addiction (2) · Smoking (2) · Smoking Cessation (2) · Stress Disorders, Post-Traumatic (2)
Behavior (32) · Mental Disorders (26) · Compulsive Behavior (19) · Chemically-Induced Disorders (15) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (8) · Substance-Related Disorders (7) · Attention Deficit and Disruptive Behavior Disorders (6) · Neurodevelopmental Disorders (6) · Neurologic Manifestations (6) · Narcotic-Related Disorders (5) · Nervous System Diseases (5) · Alcohol-Related Disorders (3) · Behavioral Symptoms (3)
Naltrexone (6) · Buprenorphine (4) · vivitrol (3) · Ascorbic Acid (2) · Buprenorphine, Naloxone Drug Combination (2) · Magnesium (2) · Topiramate (2) · Vitamin B 6 (2) · Zinc (2) · 2-(2-(2-chloro-3-(2-(3,3-dimethyl-5-sulfo-1-(4-sulfo-butyl)-3H-indol-2-yl)-vinyl)-cyclohex-2-enylidene)-ethylidene)-3,3-dimethyl-1-(4-sulfo-butyl)-2,3-dihydro-1H-indole-5-carboxylic acid (1) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Acupuncture Therapy (1) · Aripiprazole (1) · Bupropion (1) · Calorimetry, Indirect (1)
Alkermes, Inc. (3) · Assistance Publique - Hôpitaux de Paris (2) · Dartmouth-Hitchcock Medical Center (2) · Rhodes Pharmaceuticals, L.P. (2) · BioDelivery Sciences International (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Federal University of São Paulo (1) · Johns Hopkins University (1) · Kieran Cooley (1) · King's College London (1) · Medical University of South Carolina (1) · Nantes University Hospital (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Pharmasoft (1) · Population Health Research Institute (1)
United States (18) · Canada (5) · France (4) · Russia (2) · Austria (1) · Brazil (1) · Taiwan (1) · United Kingdom (1)
Mark P. McGovern, Ph.D. (2) · Sharon B. Wigal, Ph.D. (2) · Umesh Jain, MD (2) · Wei-wei Chang, Ph.D. (2) · Alexander Okhapkin, Prof. (1) · Alexander Sofronov, Prof. (1) · Alexey Egorov, Prof. (1) · Andrew J. Saxon, M.D. (1) · Andrey Anipchenko, Dr. (1) · Anna N. Platonova, Cand.Med.Sci, MD (1) · Anna S. Nezabudkina, MD (1) · Bernard L. Silverman, MD (1) · David H Gustafson, PhD (1) · David Val-Laillet, MSc, PhD, HDR (1) · Dina D. Gainetdinova, Dr.Med.Sci, Prof. (1)
PMID 18259871, PMID 19195813, PMID 19356862, PMID 20048226, PMID 20732631, PMID 20869813, PMID 20942294, PMID 21142534, PMID 21204739, PMID 21371751, PMID 21524303, PMID 21529928, PMID 21918924, PMID 22088886, PMID 22193826, PMID 22716460, PMID 22945623, PMID 23021494, PMID 23036218, PMID 23106923, PMID 23106924, PMID 23106925, PMID 23106926, PMID 23106927, PMID 23106928, PMID 23106929, PMID 23106930, PMID 23106931, PMID 23159524, PMID 23279924, PMID 23316787, PMID 23378669, PMID 23523131, PMID 23701526, PMID 23761390, PMID 23786504, PMID 24618688, PMID 25243237, PMID 25470572, PMID 25846251, PMID 25877989, PMID 25901451, PMID 26286351, PMID 26948856, PMID 27213949, PMID 27681711, PMID 28549161, PMID 30032945, PMID 30865304, PMID 32450497
K01DA019446 (1), P20DA024157 (1), P50AA010761 (1), P50DA009253 (1), R01DA015764 (1), R01DA020832 (1), R01DA027650 (1), R01DA030102 (1), U10DA013045 (1)